Lisinopril description, usages, side effects, indications, overdosage, supplying and lots more!

Menu
Search

Lisinopril

REMEDYREPACK INC.


FULL PRESCRIBING INFORMATION: CONTENTS*




FULL PRESCRIBING INFORMATION

BOXED WARNING

USE IN PREGNANCY
WARNINGS, Fetal/Neonatal Morbidity and Mortality

LISINOPRIL DESCRIPTION



Lisinopril








CLINICAL PHARMACOLOGY

PRECAUTIONS




Pharmacokinetics and Metabolism:



DOSAGE AND ADMINISTRATION



Pharmacodynamics and Clinical Effects:

Hypertension:
WARNINGS





PRECAUTIONS

DOSAGE AND ADMINISTRATION

Heart Failure:



Acute Myocardial Infarction:

DOSAGE AND ADMINISTRATION


ADVERSE REACTIONS - Acute Myocardial Infarction

INDICATIONS & USAGE




WARNINGS
WARNINGS, Anaphylactoid and Possibly Related Reactions

LISINOPRIL CONTRAINDICATIONS



WARNINGS

Anaphylactoid and Possibly Related Reactions:


Head and Neck Angioedema:
ADVERSE REACTIONS

Intestinal Angioedema:

INDICATIONS AND USAGECONTRAINDICATIONS

Anaphylactoid Reactions During Desensitization:


Anaphylactoid Reactions During Membrane Exposure:



Hypotension:
DOSAGE AND ADMINISTRATION
PRECAUTIONS, Drug InteractionsADVERSE REACTIONS




Leukopenia/Neutropenia/Agranulocytosis:


Hepatic Failure:


Fetal/Neonatal Morbidity and Mortality:







PRECAUTIONS

General

Aortic Stenosis/Hypertrophic Cardiomyopathy:


Impaired Renal Function:




DOSAGE AND ADMINISTRATION

Hyperkalemia:
Drug Interactions.)

Cough:


Surgery/Anesthesia:


INFORMATION FOR PATIENTS




PRECAUTIONS, Drug Interactions




DRUG INTERACTIONS

WARNINGSDOSAGE AND ADMINISTRATIONDOSAGE AND ADMINISTRATION







CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY






PREGNANCY

WARNINGS, Fetal/Neonatal Morbidity and Mortality

NURSING MOTHERS



PEDIATRIC USE


CLINICAL PHARMACOLOGY, Pharmacokinetics and MetabolismPharmacodynamics and Clinical EffectsDOSAGE AND ADMINISTRATION

GERIATRIC USE


CLINICAL PHARMACOLOGYPharmacodynamics and Clinical EffectsHeart FailureCLINICAL PHARMACOLOGYPharmacodynamics and Clinical EffectsAcute Myocardial Infarction

CLINICAL PHARMACOLOGYPharmacokinetics and Metabolism
DOSAGE AND ADMINISTRATION


LISINOPRIL ADVERSE REACTIONS



Hypertension





Heart Failure







Acute Myocardial Infarction




WARNINGS, Anaphylactoid Reactions and Possibly Related ReactionsWARNINGS, Hypotension
Digestive: Pancreatitis, hepatitis (hepatocellular or cholestatic jaundice) (seeWARNINGS, Hepatic Failure




PRECAUTIONS, Drug Interactions




PRECAUTIONSDOSAGE AND ADMINISTRATION

WARNINGS

WARNINGS
WARNINGS, Fetal/Neonatal Morbidity and Mortality
PRECAUTIONSCough


Clinical Laboratory Findings
PRECAUTIONS
PRECAUTIONS
WARNINGSHepatic Failure


OVERDOSAGE


WARNINGSAnaphylactoid Reactions During Membrane Exposure

DOSAGE & ADMINISTRATION

Hypertension

WARNINGS
WARNINGSPRECAUTIONSDrug Interactions
PRECAUTIONS

WARNINGS, Anaphylactoid Reactions During Membrane Exposure


Heart Failure
WARNINGSPRECAUTIONS, Drug Interactions

WARNINGSPRECAUTIONS, Drug Interactions

Acute Myocardial Infarction

WARNINGSDOSAGE AND ADMINISTRATION, Heart Failure


Use in Elderly


Pediatric Hypertensive Patients6 years of age
CLINICAL PHARMACOLOGY, Pharmacokinetics and MetabolismPharmacodynamicsClinical Effects.
CLINICAL PHARMACOLOGY, Pharmacokinetics and MetabolismPharmacodynamics and Clinical EffectsPRECAUTIONS

HOW SUPPLIED









Storage










PACKAGE LABEL.PRINCIPAL DISPLAY PANEL SECTION














Lisinopril






Lisinopril














Lisinopril






Lisinopril

Lisinopril TABLET

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:49349-158(NDC:0591-0409)
Route of Administration ORAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
LISINOPRIL LISINOPRIL ANHYDROUS 40 mg

Inactive Ingredients

Ingredient Name Strength
SILICON DIOXIDE
DIBASIC CALCIUM PHOSPHATE DIHYDRATE
MAGNESIUM STEARATE
mannitol
FD&C YELLOW NO. 5

Product Characteristics

Color Size Imprint Code Shape
yellow 10 mm WATSON;409 ROUND

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:49349-158-02 30 in 1 BLISTER PACK
2 NDC:49349-158-28 300 in 1 CANISTER

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANDA ANDA076059 2011-04-20


PLEASE, BE CAREFUL!
Be sure to consult your doctor before taking any medication!
Copyright © 2014. drugs-library.com. All rights reserved. Information on drugs-library.com is provided for educational purposes only and is not to be used for medical advice, diagnosis or treatment.
Support info@drugs-library.com.